Neurocrine Biosciences

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation (öffnet in neuem Tab)

  ChartMill · 02.10.2026

• Neurocrine advances research on VYKAT XR for Pr... (öffnet in neuem Tab)

  Pluang · 30.09.2026

• Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference (öffnet in neuem Tab)

  PR Newswire · 30.09.2026

• Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return (öffnet in neuem Tab)

  Simply Wall Street · 30.09.2026

• Neurocrine Biosciences selects Ruder Finn as communications AOR (öffnet in neuem Tab)

  Medical Marketing and Media · 29.09.2026

• UBS cuts Neurocrine Biosciences stock price target to $214 on competition (öffnet in neuem Tab)

  Investing.com · 29.09.2026

• ETFs Investing in Neurocrine Biosciences, Inc. Stocks (öffnet in neuem Tab)

  TradingView · 29.09.2026

• Ruder Finn Wins Neurocrine Biosciences US AOR (öffnet in neuem Tab)

  PRovoke Media · 29.09.2026

• Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return (öffnet in neuem Tab)

  Simply Wall Street · 29.09.2026

• Neurocrine Biosciences names Eiry Roberts as chief medical officer (öffnet in neuem Tab)

  Investing.com · 28.09.2026

• Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer (öffnet in neuem Tab)

  marketscreener.com · 28.09.2026

• Neurocrine names Eiry Roberts chief medical officer (öffnet in neuem Tab)

  Stock Titan · 28.09.2026

• Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes (öffnet in neuem Tab)

  marketscreener.com · 28.09.2026

• Neurocrine Biosciences names Eiry W. Roberts as Chief Medical Officer, replacing Sanjay Keswani. (öffnet in neuem Tab)

  Pluang · 28.09.2026

• Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer (öffnet in neuem Tab)

  PR Newswire · 28.09.2026

• Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? (öffnet in neuem Tab)

  Eastern Progress · 23.09.2026

• Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story (öffnet in neuem Tab)

  Yahoo Finance · 17.09.2026

• Neurocrine Biosciences' CCO Eric Benevich Reports Share Award and Forfeiture on September 11, 2026 (öffnet in neuem Tab)

  Kalkine Media · 16.09.2026

• Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock (öffnet in neuem Tab)

  Investing.com · 16.09.2026

• CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests (öffnet in neuem Tab)

  Stock Titan · 15.09.2026

• Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale (öffnet in neuem Tab)

  Stock Titan · 15.09.2026

• PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares (öffnet in neuem Tab)

  Stock Titan · 15.09.2026

• Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale (öffnet in neuem Tab)

  Stock Titan · 14.09.2026

• Neurocrine Biosciences at Wells Fargo conference: growth story broadens (öffnet in neuem Tab)

  Investing.com · 09.09.2026

• Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says (öffnet in neuem Tab)

  Yahoo Finance · 08.09.2026

• Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run (öffnet in neuem Tab)

  Simply Wall Street · 06.09.2026